Cochrane Abstracts
Chemotherapy plus Rituximab versus chemotherapy alone for B‐cell non‐Hodgkin's lymphoma
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Chemotherapy Plus Rituximab Versus Chemotherapy Alone for B‐cell non‐Hodgkin's Lymphoma." Cochrane Abstracts, John Wiley & Sons, Inc, 2026. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/436895/all/Chemotherapy_plus_Rituximab_versus_chemotherapy_alone_for_B‐cell_non‐Hodgkin's_lymphoma.
Chemotherapy plus Rituximab versus chemotherapy alone for B‐cell non‐Hodgkin's lymphoma. Cochrane Abstracts. John Wiley & Sons, Inc; 2026. https://evidence.unboundmedicine.com/evidence/view/Cochrane/436895/all/Chemotherapy_plus_Rituximab_versus_chemotherapy_alone_for_B‐cell_non‐Hodgkin's_lymphoma. Accessed January 18, 2026.
Chemotherapy plus Rituximab versus chemotherapy alone for B‐cell non‐Hodgkin's lymphoma. (2026). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/436895/all/Chemotherapy_plus_Rituximab_versus_chemotherapy_alone_for_B‐cell_non‐Hodgkin's_lymphoma
Chemotherapy Plus Rituximab Versus Chemotherapy Alone for B‐cell non‐Hodgkin's Lymphoma [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2026. [cited 2026 January 18]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/436895/all/Chemotherapy_plus_Rituximab_versus_chemotherapy_alone_for_B‐cell_non‐Hodgkin's_lymphoma.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Chemotherapy plus Rituximab versus chemotherapy alone for B‐cell non‐Hodgkin's lymphoma
ID - 436895
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/436895/all/Chemotherapy_plus_Rituximab_versus_chemotherapy_alone_for_B‐cell_non‐Hodgkin's_lymphoma
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
